- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking to the Future in MD Treatment
Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down rather than restore gene expression for these autosomal dominant conditions.
EP: 1.Advancements & Challenges in Muscular Dystrophy Treatment
EP: 2.Data on Duchenne Muscular Dystrophy Treatment From MDA 2025
EP: 3.Key Takeaways From DMD Treatment Data
EP: 4.Overview of Spinal Muscular Atrophy
EP: 5.Gaps in Care for Childhood SMA
EP: 6.The Impact of Intrathecal Onasemnogene Abeparvovec Therapy in SMA
EP: 7.Looking to the Future in MD Treatment
EP: 8.The Patient Perspective
EP: 9.MD Treatment From a Managed Care Perspective
Looking to the Future in DMD Treatment
The most exciting developments in muscular dystrophy research involve applying proven therapeutic technologies to other genetic muscular dystrophy conditions beyond Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). The same foundational approaches—antisense oligonucleotides, siRNA, and gene transfer therapy—are being adapted for treatment of additional muscular dystrophies that have significant unmet medical needs. This expansion represents a natural evolution of successful therapeutic strategies, leveraging the scientific advances and clinical experience gained from DMD and SMA treatments to address a broader spectrum of neuromuscular diseases.
Two particularly promising targets for these emerging therapies are facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy, both relatively common muscular dystrophies that cause severe disability. These conditions present unique therapeutic challenges as autosomal dominant disorders, requiring a different strategic approach compared with the gene replacement strategies used in DMD and SMA. Instead of restoring gene expression, the therapeutic focus shifts to knocking down problematic gene activity, though the underlying technological platforms remain similar. This adaptation demonstrates the versatility of current gene therapy and oligonucleotide technologies in addressing different genetic mechanisms.
The future outlook for muscular dystrophy treatment appears highly promising, with expectations of significant data releases in the coming years. Patients with these conditions represent populations with severe unmet needs who are eager to participate in clinical studies, creating favorable conditions for rapid research progress. The combination of established therapeutic platforms, clear patient populations, and demonstrated willingness to participate in research suggests that transformative treatments for FSHD, myotonic dystrophy, and other muscular dystrophies may be achievable in the near future. This expansion of therapeutic options could fundamentally change the treatment landscape for multiple muscular dystrophy conditions, offering hope to patient populations that have historically had limited treatment options.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
